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ABSTRACT: The conformational analysis of glycosidases
aﬀords a route to their speciﬁc inhibition through
transition-state mimicry. Inspired by the rapid reaction
rates of cyclophellitol and cyclophellitol aziridineboth
covalent retaining β-glucosidase inhibitorswe postulated
that the corresponding carba “cyclopropyl” analogue
would be a potent retaining β-glucosidase inhibitor for
those enzymes reacting through the 4H3 transition-state
conformation. Ab initio metadynamics simulations of the
conformational free energy landscape for the cyclopropyl
inhibitors show a strong bias for the 4H3 conformation,
and carba-cyclophellitol, with an N-(4-azidobutyl)-
carboxamide moiety, proved to be a potent inhibitor (Ki
= 8.2 nM) of the Thermotoga maritima TmGH1 β-
glucosidase. 3-D structural analysis and comparison with
unreacted epoxides show that this compound indeed binds
in the 4H3 conformation, suggesting that conformational
strain induced through a cyclopropyl unit may add to the
armory of tight-binding inhibitor designs.
T he diverse conformational pathways of glycosidases
1,2 (for
example, Figure 1A) coupled to their phenomenal
transition-state stabilization3 oﬀer a powerful route to selective
enzyme inhibition. One of the main goals of the ﬁeldvery
rarely achievedis to design and apply conformationally
restricted inhibitors in order to provide both potency and
speciﬁcity; conformationally biased inhibitors that target
speciﬁc classes of glycoside hydrolase (GH) would be of
considerable use as cellular and mechanistic probes with
potential as starting points for therapeutic compounds.
Cyclophellitol (1, Figure 1), isolated in 1990 from the
mushroom Phellinus sp.,4 is a potent mechanism-based inhibitor
of retaining β-glucosidases. It ﬁnds primary use as a covalent
inactivator of β-glucosidases.5 Cyclophellitol is a conﬁgurational
analogue of β-glucopyranose, but its conformational behavior is
diﬀerent. Whereas β-glucopyranoses prefer to adopt a 4C1
conformation, the epoxide annulation in 1 likely enforces a
preferred 4H3 half-chair conformation onto the cyclitol moiety.
Cyclophellitol (1) is thus a potential conformational analogue
of the oxocarbenium ion transition-state during β-glucosidase-
mediated hydrolysis of a β-glucosidic linkage.
Although the mode of action of 1 is covalent (Figure 1B), its
potency and speciﬁcity as a retaining β-glucosidase inhibitor
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Figure 1. (A) Mechanistic itinerary of retaining β-glucosidases. (B)
Structure of cyclophellitol (1) adopting a 4H3 conformation and its
proposed mechanism of binding. (C) Structure of carba-cyclophellitol
(2) in 4H3 conformation.
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and its mode of action (entering the enzyme active site as a 4H3
half-chair transition-state analogue followed by SN2 displace-
ment of the epoxide heteroatom) led us to consider whether
the corresponding carba analogue (that is, substitution of the
oxygen for carbon) would result in competitive inhibitors in
which potency and potentially speciﬁcity would be accrued by
virtue of partial transition-state mimicry (Figure 1C).
To test this hypothesis, a set of carba-cyclophellitols was
designed. Here we present the synthesis of carba-cyclophellitols
3−5 (Figure 2), the quantum mechanical analysis of their
favored conformation, and their structural and inhibitory
dissection toward β-glucosidases. Carba-cyclophellitols are
shown to be low μM inhibitors. Furthermore, exploiting the
possibility of incorporating pseudoaxial R groupsconsistent
with the catalytic itinerarythat bearing a hydrophobic moiety
at the terminal cyclopropyl carbon (5) was indeed a potent
(low nM) inhibitor of a classical model β-glucosidase, namely
Thermotoga maritima TmGH1.5,6 The crystal structure of
TmGH1 containing carba-cyclophellitol 5 was determined and
compared with that of an unreacted cyclophellitol derivative; as
predicted, both bind in 4H3 conformation, which is the
presumed transition-state conformation during the TmGH1-
catalyzed hydrolysis of β-glucosidic linkages.
The synthesis of compounds 3−5 commenced with the easy
access of key intermediate 7, which was obtained via the
synthetic procedure described by the group of Madsen9 and
optimized in our laboratory (Scheme 1).8 Global benzylation of
7 gave cyclohexene 8, and cyclopropanation with ethyl
diazoacetate (EDA)10,11 under the agency of Cu(acac)2 resulted
in the formation of product 9 as a mixture of α- and β-isomers
(α/β, 2:1). After the reduction step12 the β-isomer could be
isolated by column chromatography to give alcohol 10, which
was oxidized, and ensuing esteriﬁcation yielded enantiomeri-
cally pure β-ester 11. Sequential one-pot formation and
Grignard addition onto the Weinreb amide yielded β-ketone
12. Both benzyl-protected ester 11 and ketone 12 were
subjected to palladium-catalyzed hydrogenolysis conditions in
ethyl acetate and acetic acid (11) or in methanol (12) to obtain
target compounds 3 and 4. The mixture of α- and β-esters 9
was saponiﬁed, and the resulting carboxylates were condensed
with 4-azidobutan-1-amine (see Supporting Information (SI)).
The mixture of α- and β-amides was separated by preparative
HPLC puriﬁcation. Finally, the benzyl groups were removed in
the presence of the azide with anhydrous BCl3 in dichloro-
methane to aﬀord β-amide 5.
Having carba-cyclopropane 3−5 in hand, we studied their
inhibition potency in comparison with deoxynojirimycin
(DNJ), a known competitive TmGH1 inhibitor and AMP-
DNM (MZ-21), a known human retaining β-glucosidase
inhibitor.13 Initial binding constant (Ki) values were deter-
mined on TmGH1 by monitoring the UV absorbance of p-
nitrophenolate from p-nitrophenyl β-D-glucopyranoside using
the Lineweaver−Burk method. Carba-cyclophellitol 3 and 4
showed micromolar inhibition, consistent with our design
strategy and similar to that displayed by the charged species
DNJ, whereas 5 proved to be a strong reversible binding
TmGH1 inhibitor with a Ki value of 8.2 nM, much more potent
than DNJ14 and AMP-DNM (low micromolar) (Table 1 and
Figure S4). We then explored the activity of compound 5 in
human lysosomal retaining β-glucosidase, GBA1 (deﬁciency of
which is causative of the human lysosomal storage disorder,
Gaucher disease) with an apparent IC50 ≈ 100 μM. No
apparent inhibition of the human lysosomal α-glucosidase,
GAA (deﬁcient in the human glycogen storage disease, Pompe
disease) was observed at ﬁnal concentrations of 5 up to 150
μM. Thus, although less potent for GBA1 than for the bacterial
enzyme tested, compound 5 appears to have selectivity for the
human lysosomal β-glucosidase over the human lysosomal α-
glucosidase, which is opposite of the selectivity observed for
DNJ (Table 1).
Figure 2. Structures of carba-cyclophellitols 3−5 and 8-azidocyclo-
phellitol (6, KY1707,8).
Scheme 1. The synthesis of carba-cyclophellitols 3-5a
aReagents and conditions: (a) BnBr, NaH, TBAI, DMF, 0 °C to rt, 24
h, 94%; (b) EDA, Cu(acac)2, EtOAc, (35%, 2:1, as a mixture of α/β);
(c) DIBAL, THF, 30 min at 0 °C and then 1 h at rt, 13%; (d) Jones
reagent, acetone, 0 °C, 3 h, 53%; (e) EtOH, N,N-diisopropylcarbo-
diimide, 4-dimethylaminopyridine, toluene, rt, 4 h, 62%; (f) Pd(OH)2/
C, H2, EtOAc, AcOH, rt, overnight, 81%; (g) N,O-dimethylhydroxyl-
amine hydrochloride, EtMgBr, THF, 48%; (h) Pd(OH)2/C, H2,
MeOH, rt, overnight, (58%); (i) i) LiOH, MeOH, H2O, rt, overnight;
ii) 4-azidobutan-1-amine (see SI), DIPEA, HCTU, CH2Cl2, rt,
overnight; (j) BCl3, DCM, 99%.
Table 1. Apparent IC50 Values and Inhibitory Constants (Ki)
for in Vitro Inhibition of α- and β-Glucosidase Activity by
Compounds 3−5, DNJ, and AMP-DNM
Ki
a app IC50
compound TmGH1b GBA1c GAAc
3 22.3 μM >150 μM >150 μM
4 88.9 μM >150 μM >150 μM
5 8.20 nM 99 ± 1.9 μM >150 μM
DNJ 2.50 μMd 109 ± 1.0 μMe 1.5 μMg
AMP-DNM (MZ-21) 4.97 μM 156 ± 16 nMf 0.4 μMg
aKm TmGH1 = 0.24 mM.
bThe assay was performed with p-NPG as
substrate. cThe assay was performed with 2,4-DNPG as substrate.
Values in agreement with literature. dKi DNJ = 3.8 μM in TmGH1.
14
eIC50 DNJ = 250 μM in GBA1.
15 fIC50 AMP-DNM = 100−200 nM in
GBA1.15,16 gValues from ref 17. App: apparent.
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Inspired by the low μM to nM inhibition of TmGH1 by the
carba-cyclopropanes, we sought to determine whether the
cyclopropyl moiety indeed biased the conformation to 4H3. We
calculated the conformational free energy landscape (FEL) for
generic cyclopropyl (2, R = H) by ab initio metadynamics (see
SI), and the Cremer−Pople puckering coordinates θ and ϕ
were used as collective variables, yielding a Mercator
representation for the FEL (as used previously for diverse
glycosidase inhibitors18−20), Figure 3A. Compound 2 clearly
favors the 4H3 conformation in vacuo, with the ﬂipped
3H4 form
in another local energy minimum. Subsequent to FEL
calculation, we compared the experimental J values of several
(cyclohexane) ring protons of compound 4 with their
calculated counterparts, in which calculations were performed
on compound 4 in the 4H3 conformation. Both sets of values
are in good agreement, which underscores the notion that
compound 4, and by extension also the other compounds
subject of this Communication (whose 1H NMR spectra give
broadened signals due to the amide presentsee SI) do indeed
adopt the 4H3 conformation in solution.
Structural dissection of the inhibitory action of 5, and the
conceptual link through to cyclophellitol 1, was achieved ﬁrst
by rapid soaking (as opposed to preincubation as used
previously to trap the covalent adduct5) of crystals of
TmGH1 with cyclophellitol derivative KY1707,8 (6). Serendip-
itously, this indeed aﬀorded the unreacted cyclophellitol KY170
in 4H3 conformation, with the nucleophile poised to attack,
Figure 3B, conﬁrming our hypothesis that (unreacted)
cyclophellitols adopt a transition-state like 4H3 conformation.
In order to dissect similar mimicry by carba-cyclopropane 5,
and conﬁrm the FEL calculated by ab initio metadynamics,
TmGH1 crystals were soaked with carba-cyclophellitol 5 and
the subsequently obtained structure was analyzed and solved
with X-ray crystallography. The obtained electron density
pattern clearly demonstrates the presence of carba-cyclo-
phellitol 5 in the active site in 4H3 conformation (Figure 3C;
the butyl azide moiety is mobile and diﬀerently disordered in
the structure and not shown for clarity).
Overlay of cyclophellitol derivative KY170 with carba-
cyclophellitol 5 (Figure 3D) shows almost perfect coincidence
of atomic positions, showing that, as suggested by the FEL, 5 is
a permanent mimic of cyclophellitol posted in the active site
prior to nucleophilic attack.
The improved binding of 5, relative to 3 and 4 presumably
stems from desolvation caused by the alkyl-azido “tail” sitting in
the aglycone site. One of the design advantages of the carba-
cyclopropanes is that any pendent R groups are disposed
pseudoaxial to the sugar ring, consistent with the distortions
seen during catalysis which presumably adds to their
augmentation of binding. The 3-D structure with 5 conﬁrms
this and shows a lateral, antitrajectory interaction of the
catalytic amino acid Glu166 with the pseudoaxially disposed
amide of 5. There are four molecules of TmGH1 in the
crystallographically observed asymmetric unit. While they all
show the R group axial, they all show diﬀerent degrees of
disorder of this alkyl region itself. In one molecule, there is
essentially no electron density for the tail, while in two
molecules the chain passes through the aglycon region (that is
ﬂanked by Val169, Trp168, and Trp324), making nonspeciﬁc
interactions with this region. In the fourth molecule of the AU,
the alkyl azido chain appears to follow two separate routes
along each hydrophobic ﬂank of the substrate binding cleft.
Bicyclic cyclopropyl glucosidase inhibitors, with the bridge
between the “C6” and “O5” atoms, were ﬁrst proposed by
Tanaka and co-workers21 and later developed in galacto
conﬁguration by Bennet and co-workers and found to be
good α-glucosidase and galactosidase inhibitors, respectively.22
More recently, activated forms of these compounds have been
used as covalent inhibitors.23 In these cases the conformational
restriction limits the accessible conformations to “oﬀ-pathway”
3H2 and
2H3 half-chairs
23 (or perhaps their related 1,4 boats)
recently elegantly revealed by X-ray crystallography.24 Further,
Stick and Stubbs25 synthesized a bicyclic cyclopropyl inhibitor
with the bridge between the “anomeric” C1 carbon position
and the “C2” atom with a millimolar Ki value. The carba-
cyclophellitol derivatives presented here oﬀer, by virtue of the
advantage of their conformational restriction between the “O5”
and “anomeric” C1 carbon positions, a potent inhibitor in
which the conformational restraint is a glycosidase reaction
coordinate relevant 4H3. Given the large number of glycosidase
inhibitors in medical use, including those being developed as
pharmacological chaperones and as diagnostic tools, the
harnessing of appropriate conformation restraint, coupled to
Figure 3. (A) A mercator representation for the computed free energy
landscape (FEL) of cyclopropyl (2, R = H) (θ and ϕ are given in
degrees). (B) Crystal structure of TmGH1 in complex with unreacted
6, KY170. (C) Crystal structure of TmGH1 in complex with carba-
cyclophellitol 5, showing the carba-cyclophellitol CO-NH group.
Electron density maps for both (B) and (C) are maximum likelihood/
σA weighted 2Fobs − Fcalc syntheses contoured at 1.4σ. (D) Overlay of
(B) in ice blue on (C) in coral.
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correct stereochemistry, should add greatly to the enzymo-
logical, cellular, and, ultimately, therapeutic toolbox.
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Thompson, A. J.; Lowe, E. C.; White, J. M.; Gilbert, H. J.; Rovira, C.;
Davies, G. J.; Williams, S. J. Angew. Chem., Int. Ed. 2014, 53, 1087.
(21) Tanaka, K. S. E.; Winters, G. C.; Batchelor, R. J.; Einstein, F. W.
B.; Bennet, A. J. J. Am. Chem. Soc. 2001, 123, 998.
(22) Wang, Y.; Bennet, A. J. Org. Biomol. Chem. 2007, 5, 1731.
(23) Chakladar, S.; Wang, Y.; Clark, T.; Cheng, L.; Ko, S.; Vocadlo,
D. J.; Bennet, A. J. Nat. Commun. 2014, 5, 5590.
(24) Adamson, C.; Pengelly, R. J.; Shamsi Kazem Abadi, S.;
Chakladar, S.; Draper, J.; Britton, R.; Gloster, T. M.; Bennet, A. J.
Angew. Chem. 2016, 128, 15202.
(25) Stick, R. V.; Stubbs, K. A. J. Carbohydr. Chem. 2005, 24, 529.
Journal of the American Chemical Society Communication
DOI: 10.1021/jacs.7b01773
J. Am. Chem. Soc. 2017, 139, 6534−6537
6537
